Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 11/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 4/20 | 0.54 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050016 | 1.00 | AKT2 (0.63) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL24909154 | 0.94 | JAK3 (0.62) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL31050017 | 0.87 | JAK3 (0.60) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL3952874 | 0.79 | JAK3 (0.75) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL10074309 | 0.78 | DOT1L (0.85) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL15178732 | 0.78 | DOT1L (0.85) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL3953429 | 0.78 | JAK3 (0.65) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL31732396 | 0.78 | JAK3 (0.63) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL1003408 | 0.78 | AKT2 (1.00) | AKT2GSK3BKITJAK3LCK | |
| SCHEMBL2022699 | 0.78 | AKT2 (0.78) | AKT2GSK3BKITJAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360157-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2024-10-31 | — | — | US | disclosed |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122922-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| EP-2451813-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | Leo Pharma A/S (DK) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | AKT2 703/4885GSK3B 842/4885KIT 327/4885 |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | WEE2, AKT1S1, WEE1 | AKT2 4/4885GSK3B 32/4885KIT 81/4885 |
| US-20240360157-A1 | TYK2 INHIBITORS | TYK2, JAK2, ABL1 | AKT2 564/4885GSK3B 118/4885KIT 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.